Adult Glioblastoma Clinical Trial
Official title:
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
This phase I/II trial is studying the side effects and best dose of tandutinib and to see how well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PRIMARY OBJECTIVES:
I. Assess the ability of tandutinib to achieve a target tumor/plasma ratio ≥ 0.33 in
patients with recurrent glioblastoma undergoing resection. (Feasibility study) II. Detect
potential biological effects of tandutinib by measuring platelet-derived growth factor
receptor phosphorylation status and downstream activation of Akt and Erk. (Feasibility
study) III. Determine the maximum tolerated dose of tandutinib in patients with recurrent or
progressive glioblastoma. (Phase I) IV. Estimate the frequency of toxicities associated with
tandutinib in patients with recurrent or progressive glioblastoma. (Phase I) V. Describe the
pharmacokinetics of this route of administration in patients with recurrent or progressive
glioblastoma. (Phase I) VI. Assess tumor response rate in patients with recurrent or
progressive glioblastoma. (Phase II)
SECONDARY OBJECTIVES:
I. Estimate overall survival of patients with recurrent or progressive glioblastoma. (Phase
II) II. Estimate the 6-month progression-free survival rate in these patients. (Phase II)
III. Assess the toxicities associated with tandutinib in these patients. (Phase II) IV.
Assess the pharmacokinetic profile of this route of administration in these patients. (Phase
II) V. Explore protein-expression patterns that distinguish patients who respond to therapy
from those who do not. (Phase II)
OUTLINE: This is a multicenter, prospective, nonrandomized, feasibility study and phase I
study (in parallel) followed by an open label phase II study.
FEASIBILITY STUDY: Patients receive oral tandutinib twice daily for 7 days. Patients then
undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery,
patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in
the absence of disease progression or unacceptable toxicity.
PHASE I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28
days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
[Note: *On day 1 of course 1, patients receive only 1 dose of tandutinib.]
PHASE II: Patients receive tandutinib as in phase I at the MTD determined in phase I.
Patients undergo blood sample collection for pharmacokinetic studies. Patients in the
feasibility portion of the study also undergo blood and tissue sample collection for
correlative studies by mass spectrometry for tandutinib concentration. Samples are also
examined for circulating endothelial cells and plasma proteins (vascular endothelial growth
factor [VEGF]-A, -B, -C, and -D, soluble VEGF receptors [sVEGFR's], placental growth factor
[P1GF], platelet-derived growth factor [PDGF]-AA, PDGF-AB, PDGF-BB, angiopoietin-1 and -2,
tumstatin, thrombospondin-1, and IL-8) as potential markers of the antiangiogenic effect of
tandutinib.
After completion of study treatment, patients are followed every 2 months.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02530502 -
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 1 | |
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT00238303 -
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00049387 -
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
|
Phase 1 | |
Completed |
NCT02227901 -
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT02015819 -
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
Active, not recruiting |
NCT02179086 -
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 2 | |
Recruiting |
NCT04573140 -
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
|
Phase 1 | |
Active, not recruiting |
NCT00823797 -
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
|
Phase 2 | |
Completed |
NCT00045565 -
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Completed |
NCT01977677 -
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT01648348 -
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00004262 -
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT01575275 -
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT01996527 -
3T MRI Biomarkers of Glioma Treatment Response
|
Early Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01103375 -
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
|
Phase 1 | |
Completed |
NCT01119599 -
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Completed |
NCT00459381 -
Pazopanib in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
Completed |
NCT00316849 -
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 1 |